Therapeutic antibodies: Discovery, design and deployment
Abstract
Therapeutic antibodies have come of age with major progress being made in cancer, autoimmunity and chronic inflammation, as well as a wide range of other human diseases. Antibody engineering is further driving development of novel antibody formats and genetically modified cell-based therapies that harness the power of the immune system to progress cures in otherwise intractable human diseases. Nevertheless, there are still significant challenges ahead for basic and applied research relating to therapeutic antibodies. This special issue of the journal provides reviews and opinions that relate to the discovery, design and deployment of antibodies as therapeutics.
Citation
Ramsland, P. and Hutchinson, A. and Carter, P. 2015. Therapeutic antibodies: Discovery, design and deployment. Molecular Immunology. 67 (2, Part A): pp. 1-3.
Source Title
Molecular Immunology
ISSN
School
School of Biomedical Sciences
Collection
Related items
Showing items related by title, author, creator and subject.
-
Dingjan, T.; Spendlove, I.; Durrant, L.; Scott, A.; Yuriev, E.; Ramsland, Paul (2014)Monoclonal antibodies represent the most successful class of biopharmaceuticals for the treatment of cancer. Mechanisms of action of therapeutic antibodies are very diverse and reflect their ability to engage in ...
-
Irani, V.; Guy, A.; Andrew, D.; Beeson, J.; Ramsland, Paul; Richards, J. (2015)Monoclonal antibodies are being developed as therapeutics to complement drugs and vaccines or to fill the gap where no drugs or vaccines exist. These therapeutic antibodies (ThAb) may be especially important for infectious ...
-
Flynn, J.; Sacks Davis, R.; Higgs, Peter; Aitken, C.; Moneer, S.; Suppiah, V.; Tracy, L.; Ffrench, R.; Bowden, S.; Drummer, H.; George, J.; Bharadwaj, M.; Hellard, M. (2014)Background: Detectable HCV-specific cellular immune responses in HCV antibody and RNA negative people who inject drugs (PWID) raise the question of whether some are resistant to HCV infection. Immune responses from people ...